Athenex, Inc. (ATNX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Athenex, Inc. (ATNX) trades at $0.2031 with AI Score 46/100 (Grade C). Athenex, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of cancer treatments. Market cap: $2.33M, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for ATNX: ATNX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ATNX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ATNX: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Athenex, Inc. (ATNX) Healthcare & Pipeline Overview
Athenex, Inc., a biopharmaceutical company, focuses on developing innovative therapies for cancer treatment, operating through its Oncology Innovation, Global Supply Chain, and Commercial Platforms. Its lead drug candidates target metastatic breast cancer and other advanced malignancies, positioning it within the competitive specialty and generic drug market.
What Is the Investment Thesis for ATNX?
Athenex, Inc. presents a high-risk, high-reward investment opportunity within the biopharmaceutical sector. The company's Orascovery platform, particularly oral paclitaxel with encequidar, holds promise in treating metastatic breast cancer, with Phase III trial results being a critical value driver. Successful commercialization of Tirbanibulin ointments for actinic keratosis could provide a near-term revenue stream. However, the company's negative profit margin of -96.3% and reliance on clinical trial outcomes introduce significant financial and regulatory risks. The development of cell therapies like KUR-501 and KUR-502 offers long-term growth potential, but these are early-stage and capital-intensive. Investors should closely monitor clinical trial data, regulatory approvals, and the company's ability to secure additional funding to sustain operations.
Based on FMP financials and quantitative analysis
ATNX Key Highlights
- Athenex operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
- The company's lead product candidate, Oral paclitaxel and encequidar, is in Phase III trial for metastatic breast cancer.
- Athenex is developing KUR-501, an autologous product in Phase I clinical trial for treating children with relapsed-refractory high-risk neuroblastoma.
- The company has a negative profit margin of -96.3%, indicating significant losses.
- Athenex's gross margin is 26.0%.
Who Are ATNX's Competitors?
ATNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRK Merck & Co., Inc. | $124.41 | -2.42% | $307B | 85 |
| PFE Pfizer Inc. | $24.86 | +0.44% | $142B | 66 |
| BMY Bristol-Myers Squibb Company | $60.93 | +1.28% | $124B | 90 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.14 | +0.07% | $40.3M | 61 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATNX's Key Strengths?
- Innovative drug development platforms (e.g., Orascovery)
- Diverse pipeline of oncology therapies
- Global supply chain capabilities
- Experienced management team
What Are ATNX's Weaknesses?
- High operating losses and negative profit margin
- Reliance on clinical trial success
- Limited commercialized products
- Significant debt burden
What Could Drive ATNX Stock Higher?
- Phase III trial results for oral paclitaxel with encequidar in metastatic breast cancer.
- Regulatory approval decisions for Tirbanibulin ointments for actinic keratosis.
- Progression of KUR-501 and KUR-502 cell therapies through Phase I clinical trials.
- Expansion of the TCR-T cell therapy pipeline.
What Are the Key Risks for ATNX?
- Financial-distress signal — its Altman Z-Score of -7.50 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures for key drug candidates.
- Regulatory delays or rejections.
- Competition from established pharmaceutical companies.
- High cash burn rate and need for additional financing.
- Patent challenges and intellectual property disputes.
What Are the Growth Opportunities for ATNX?
- Orascovery Platform Expansion: Athenex's Orascovery platform, featuring oral paclitaxel and encequidar, represents a significant growth opportunity. Successful completion of Phase III trials for metastatic breast cancer and subsequent regulatory approval could lead to substantial revenue generation. The company is also exploring the platform's application in other cancers, such as cutaneous angiosarcoma and advanced gastric cancer, expanding its market reach. The global breast cancer therapeutics market is projected to reach $30 billion by 2027, offering a substantial addressable market for Athenex.
- Src Kinase Inhibitor Commercialization: The commercialization of Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis presents a near-term growth opportunity for Athenex. Actinic keratosis is a common dermatological condition, and effective treatments are in high demand. Successful market penetration and expansion of the product line could generate a steady revenue stream. The global actinic keratosis treatment market is expected to reach $6 billion by 2025, providing a favorable market environment for Athenex.
- Cell Therapy Development: Athenex's development of cell therapies, including KUR-501, KUR-502, and KUR-503, offers long-term growth potential in the emerging field of immuno-oncology. These therapies target various hematological malignancies and solid tumors, addressing unmet medical needs. While still in early stages of development, successful clinical trials and regulatory approvals could lead to transformative therapies. The global cell therapy market is projected to reach $40 billion by 2030, presenting a significant growth opportunity for Athenex.
- Global Supply Chain Platform Optimization: Athenex's Global Supply Chain Platform provides a competitive advantage by managing the manufacturing and supply of its products. Optimizing this platform to reduce costs and improve efficiency can enhance profitability and support future growth. Strategic partnerships and investments in manufacturing infrastructure can further strengthen this platform. The global pharmaceutical supply chain market is a multi-billion dollar industry, and efficient supply chain management is crucial for success.
- TCR-T Cell Therapy Pipeline: Athenex is developing a portfolio of T cell receptor (TCR)-T cell therapies that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. This innovative approach targets specific genetic mutations associated with cancer, offering the potential for personalized cancer treatments. While in early stages of development, successful clinical trials could lead to breakthrough therapies. The global TCR-T cell therapy market is expected to grow rapidly in the coming years, driven by advancements in gene editing and immunotherapy.
What Opportunities Does ATNX Have?
- Regulatory approvals for lead drug candidates
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Increasing demand for cancer therapies
What Threats Does ATNX Face?
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
What Are ATNX's Competitive Advantages?
- Proprietary drug formulations (e.g., Orascovery platform)
- Patent protection on novel therapies
- Specialized manufacturing capabilities
- Clinical data supporting drug efficacy
What Does ATNX Do?
Athenex, Inc., established in 2003 and headquartered in Buffalo, New York, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for cancer treatment. Originally named Kinex Pharmaceuticals LLC, the company rebranded as Athenex, Inc. in August 2015 to reflect its expanded focus and strategic vision. Athenex operates through three key segments: the Oncology Innovation Platform, which focuses on developing new cancer treatments; the Global Supply Chain Platform, which manages the manufacturing and supply of its products; and the Commercial Platform, which handles the sales and marketing of its therapies. Athenex's pipeline includes Orascovery, featuring oral paclitaxel and encequidar, currently in Phase III trials for metastatic breast cancer and undergoing clinical studies for other cancers like cutaneous angiosarcoma and advanced gastric cancer. Additionally, Athenex is developing Src Kinase inhibitors, such as Tirbanibulin ointments, targeting actinic keratosis, skin cancers, and psoriasis. The company is also advancing cell therapies, including KUR-501, KUR-502, and KUR-503, targeting various hematological malignancies and solid tumors. Furthermore, Athenex is exploring dual absorption enhancers and TCR-T cell therapies to broaden its oncology portfolio.
What Products and Services Does ATNX Offer?
- Discovers and develops drugs for cancer treatment.
- Commercializes oncology therapies.
- Operates an Oncology Innovation Platform for drug development.
- Manages a Global Supply Chain Platform for manufacturing and distribution.
- Runs a Commercial Platform for sales and marketing.
- Develops oral dosage forms of existing cancer drugs.
- Creates cell therapies for hematological malignancies and solid tumors.
How Does ATNX Make Money?
- Develops and patents novel cancer therapies.
- Outlicenses or commercializes approved drugs.
- Generates revenue through product sales.
- Partners with other pharmaceutical companies for development and distribution.
What Industry Does ATNX Operate In?
Athenex operates within the competitive specialty and generic drug manufacturing industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. Athenex's focus on innovative therapies, including oral formulations and cell therapies, positions it to capture a share of this growing market. However, the company faces competition from established pharmaceutical giants and smaller biotech firms, requiring strategic partnerships and efficient execution to succeed.
Who Are ATNX's Key Customers?
- Cancer patients
- Hospitals and oncology clinics
- Healthcare providers
- Pharmaceutical distributors
How Athenex, Inc. Is Valued
Athenex, Inc. carries a market capitalization of $2.33M, placing it in the micro-cap category. Relative to its peer group, ATNX's quantitative score of 46/100 is below the peer average of 73/100.
Company Profile
Athenex, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Buffalo, US. The company is led by CEO Yiu-Nam Lau F.R.C.P.,. ATNX has traded publicly since 2017.
ROE 22%Key Financial Metrics
Return on equity for Athenex, Inc. stands at 21.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.5%, showing how much profit it generates from its asset base. A current ratio of 1.09 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 4/9Financial Health
Athenex, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -7.50 places it in the distress zone, a signal of elevated financial risk.
ATNX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative drug development platforms (e.g., Orascovery)
- Diverse pipeline of oncology therapies
- Global supply chain capabilities
- Experienced management team
Bear Case
- High operating losses and negative profit margin
- Reliance on clinical trial success
- Limited commercialized products
- Significant debt burden
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ATNX Latest News
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Oct 21, 2022
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Sep 21, 2022
-
Stocks That Hit 52-Week Lows On Friday
· Aug 20, 2021
ATNX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATNX.
Price Targets
Wall Street price target analysis for ATNX.
ATNX MoonshotScore
What does this score mean?
The MoonshotScore rates ATNX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Yiu-Nam Lau F.R.C.P.,
Chief Executive Officer
Yiu-Nam Lau is the Chief Executive Officer of Athenex, Inc. He is a Fellow of the Royal College of Physicians (F.R.C.P.). His background includes extensive experience in the pharmaceutical industry, with a focus on clinical development and regulatory affairs. He has held leadership positions at various pharmaceutical companies, contributing to the development and commercialization of numerous drugs. His expertise spans across multiple therapeutic areas, including oncology and infectious diseases. He is responsible for overseeing Athenex's strategic direction and operations.
Track Record: Under Yiu-Nam Lau's leadership, Athenex has focused on advancing its clinical pipeline, particularly the Orascovery platform. Key milestones include the progression of oral paclitaxel with encequidar into Phase III trials for metastatic breast cancer. He has also overseen the development of cell therapies and the expansion of the company's global supply chain. His strategic decisions have aimed to position Athenex as a leader in innovative cancer therapies.
What Investors Ask About Athenex, Inc. (ATNX) — Healthcare
What does the AI Score mean for ATNX?
ATNX holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Athenex, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of cancer treatments. The company operates through three segments: Oncology Innovation …
What does Athenex, Inc. do?
Athenex, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer treatment. The company operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Its primary focus is on developing oral formulations of existing intravenous cancer drugs, such as paclitaxel, through its Orascovery platform.
What do analysts say about ATNX stock?
Analyst coverage of Athenex, Inc. reflects a mixed outlook, primarily due to the company's high-risk, high-reward profile. Key valuation metrics are heavily influenced by the potential success of its clinical pipeline, particularly oral paclitaxel with encequidar. Growth considerations center on regulatory approvals and commercialization efforts.
What are the main risks for ATNX?
Athenex, Inc. faces several significant risks inherent to the biopharmaceutical industry. Clinical trial failures represent a major risk, as the company's pipeline relies on positive data to advance drug candidates. Regulatory hurdles and potential delays in approvals can also impact timelines and commercialization prospects.
What are the key factors to evaluate for ATNX?
Athenex, Inc. (ATNX) holds an AI score of 46/100 (low). Not financial advice.
How frequently does ATNX data refresh on this page?
ATNX's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ATNX's recent stock price performance?
Athenex, Inc. (ATNX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug development platforms (e.g., Orascovery). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATNX overvalued or undervalued right now?
Athenex, Inc. (ATNX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ATNX before investing?
Before investing in Athenex, Inc. (ATNX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the last reported period.
- Clinical trial outcomes are inherently uncertain.